Selexis SA, a JSR Life Sciences Company, has made key promotions across its scientific and operational leadership teams. The following have been promoted: Myriam Adam, Ph.D., to vice president, operations and intellectual property; Séverine Fagète, Ph.D., to vice president, cell line development services; and Valérie Le Fourn, Ph.D., to vice president, research.

Myriam joined Selexis in 2012 as project leader, managing and coordinating research, experimental design, process completion, data treatment and reporting for partner projects. She also held roles of increasing responsibility, serving as scientist in vector engineering and later as operations program manager and operations director, coordinating partner-oriented mammalian cell line generation and whole-genome sequencing programs. Previously, Myriam was a scientist at École Polytechnique fédérale de Lausanne (EPFL) and project leader, gene expression and analytics at ExcellGene SA.

Séverine joined Selexis in 2015 as director, cell line services, leading the bioprocess and analytics departments. She ensures the continuous generation of high-performance stable cell lines, including recombinant protein characterization. Séverine also works on providing scale-down bioreactor data using ambr® 15 to facilitate the transfer to contract manufacturing organizations (CMOs). Séverine earned her PhD in protein engineering from a private company, Novimmune, where she focused on the generation of broad-spectrum chemokine inhibitors by using directed mutagenesis, phage display isolation, functional characterization and epitope mapping.

Valérie joined Selexis in 2010 as director, cell culture addressing specific secretion bottlenecks of difficult-to-express recombinant proteins. Valérie received her PhD from the University of Aix-Marseille II, where she focused on human thrombopoietin (hTPO) maturation and the role of endoplasmic reticulum (ER) chaperones in the folding/degradation machineries of this difficult-to-express glycoprotein. After completing her PhD, Valérie held a postdoctoral position at the UniversitätsSpital Zürich, where she described a selective autophagy-mediated mechanism of misfolded and aggregated proteins that are retained in the ER compartment.